Clinical Trial Detail

NCT ID NCT03130959
Title An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

malignant glioma

malignant ependymoma

central nervous system cancer

medulloblastoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult senior

No variant requirements are available.